Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences Q1 2027 Earnings Report

HeartSciences logo
$3.13 +0.33 (+11.82%)
As of 11:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.72
Beat/Miss
N/A
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q1 2027
Date
9/10/2026
Time
Before Market Opens
Conference Call Date
Friday, September 11, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

HeartSciences Earnings Headlines

HeartSciences Inc.: Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69354233-heartsciences-inc-fortitude-invests-dollar-1-0-million-in-heartsciences-at-a-22-premium-with-no-adjustment-to-the-merger-consideration-399.htm
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fortitude-invests-1-0-million-130000623.html
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
August 24 at 1:00 AM  |  Porter & Company (Ad)
HeartSciences Announces $1 Million Fortitude Investment at 22% Premium Ahead of Proposed Merger
August 19, 2026  |  quiverquant.comQ
HeartSciences Completes Private Placement to Support Merger
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-completes-private-placement-to-support-merger?utm_source=marketbeat.com&utm_medium=referral
HeartSciences Receives Nasdaq Notice on Equity Noncompliance
August 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-receives-nasdaq-notice-on-equity-noncompliance?utm_source=marketbeat.com&utm_medium=referral
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools